康希诺: 2024年度募集资金存放与实际使用情况专项报告 | 证券代码：688185 证券简称：康希诺 | 公告编号：2025-011 | | --- | --- | | 康希诺生物股份公司 | | 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）董事会根据中国证券监督管理委 员会（以下简称"证监会"）《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》及《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》等有关规定，编制了截至 2024 年 12 月 31 日止公开发行 A 股股票 募集资金存放与实际使用情况的专项报告。现将截至 2024 年 12 月 31 日止募集 资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 经中国证监会《关于同意康希诺生物股份公司首次公开发行股票注册的批复》 （证监发行字20201448 号文）核准，公司在上海证券交易所公开发行人民币普 通股（A 股）股票 24,800,000 股，每股发行价格为人民币 209.71 ...

康希诺: 关于续聘会计师事务所的公告 证券代码：688185 证券简称：康希诺 公告编号：2025-008 康希诺生物股份公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 康希诺生物股份公司（以下简称"公司"）拟续聘德勤华永会计师事务 所（特殊普通合伙）（以下简称"德勤华永"）为2025年度境内审计机构及内部 控制审计机构，拟续聘德勤·关黄陈方会计师行（以下简称"德勤香港"）为2025 年度境外审计机构。 一、拟续聘会计师事务所的基本情况 公司拟续聘德勤华永为 2025 年度境内审计机构及内部控制审计机构，德勤 香港为 2025 年度境外审计机构。德勤华永和德勤香港的情况如下： （一）机构信息 （1）基本信息 德勤华永的前身是 1993 年 2 月成立的沪江德勤会计师事务所有限公司，于 批准转制成为特殊普通合伙企业。德勤华永注册地址为上海市黄浦区延安东路 德勤华永具有财政部批准的会计师事务所执业证书，并经财政部、中国证监 会批准，获准从事 H 股企业审计业务。德勤华永已根据财政部和中国证监会《会 计 ...

康希诺: 关于2025年度对外担保预计的公告 证券代码：688185 证券简称：康希诺 公告编号：2025-010 康希诺生物股份公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 按照公司上市地监管规则和《康希诺生物股份公司章程》《对外担保决策制 度》的相关规定，为满足康希诺生物股份公司（以下简称"公司"）合并报表范 围内下属子公司的经营发展需要，公司及全资子公司康希诺生物（上海）有限公 司拟在 2025 年度对下属子公司康希诺（上海）生物科技有限公司、康希诺（上 海）生物研发有限公司提供合计累计不超过人民币 1 亿元的担保。 康希诺生物股份公司董事会 相关担保事项以正式签署的担保文件为准，授权期限为本次董事会审议通过 之日起 12 个月内。 公司拟提请董事会授权董事长在上述额度及决议有效期内行使担保决策权、 签署相关文件等事宜，具体事项由公司财务管理中心负责组织实施。 关于 2025 年度对外担保预计的公告 截至本公告披露日，公司对外担保的总额为 46,802.36 万元，占公司最近一 期经审计净资产和总 ...

Core Viewpoint - The company has engaged Deloitte Huayong as its domestic audit firm and Deloitte Hong Kong as its overseas audit firm for the 2024 fiscal year, evaluating their compliance and effectiveness in fulfilling their duties [1][2]. Qualification Conditions - Deloitte Huayong has been operating since 1993 and was transformed into a special general partnership in 2012, with a registered address in Shanghai [1]. - Deloitte Huayong holds a practicing certificate approved by the Ministry of Finance and is authorized to conduct audits for H-share companies [2]. - The firm reported a total audited business income of RMB 4.1 billion in 2023, with audit service income of RMB 3.2 billion and securities service income of RMB 600 million [2]. Professional Record - Key partners and signing accountants have extensive experience, with the project partner Yang Juleng having over 16 years in audit services and the signing accountant Sun Weiqin having over 12 years [3][4]. - Deloitte Hong Kong has been registered as a public interest entity auditor since October 2019 and has obtained a temporary audit business license for mainland China [3]. Quality Management Level - Deloitte Huayong has established a comprehensive quality management system to ensure compliance with legal and professional standards [6][7]. - The firm implements a partner-led audit delivery model to enhance audit quality and has a clear mechanism for resolving disagreements among team members [7][8]. Work Plan - The audit plan for the year was comprehensive and operationally strong, focusing on key areas such as revenue recognition and asset impairment [10]. - Deloitte Huayong and Deloitte Hong Kong effectively communicated with the audit committee and completed all tasks on time [10]. Human and Other Resource Allocation - A dedicated audit team with extensive experience in the biopharmaceutical industry was assigned, ensuring that all team members hold relevant professional qualifications [10][11]. Information Security Management - The company has set specific clauses in the contract regarding information security responsibilities and has obtained ISO27001 certification for its information security management system [11]. Risk Bearing Capacity Level - Deloitte Huayong has a professional liability insurance coverage exceeding RMB 200 million, meeting regulatory requirements [11].

（以下简称"《公司章程》"）、 《康希诺生物股份公司独立非执 行董事工作制度》的相关规定，诚信、勤勉、独立地履行职责，及时、全面、深 入地了解公司运营状况，亲自出席董事会及各专门委员会会议，认真审议各项议 案，发表独立客观意见，促进董事会规范运作和公司治理水平提升，切实维护公 司整体利益和中小股东合法权益。现将 2024 年度履行职责情况报告如下： 康希诺: 独立董事2024年度述职报告（张耀樑） 康希诺生物股份公司 独立董事 2024 年度述职报告 本人为康希诺生物股份公司（以下简称"公司"）第三届董事会独立董事。 报告期内，本人根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股票上市 规则》《上市公司独立董事管理办法》等有关法律法规及规范性文件及《康希诺 生物股份公司章程》 一、独立董事的基本情况 本人的基本情况如下：Yiu Leung Andy CHEUNG（张耀樑）先生，1959 年 出生，加拿大国籍，拥有中国香港特别行政区护照及中国香港永久居留权，会计 及金融硕士，香港会计师公会会员。2009 年至 2010 年，任安永 ...

康希诺: 第三届董事会第六次会议决议公告 证券代码：688185 证券简称：康希诺 公告编号：2025-006 康希诺生物股份公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 康希诺生物股份公司（以下简称"公司"）第三届董事会第六次会议于 2025 年 3 月 25 日在公司会议室以现场及通讯方式召开，会议通知已于会议召开 10 日 前以电子邮件形式送达全体董事。本次会议由董事长 XUEFENG YU（宇学峰）博 士召集，应到董事 7 人，实到董事 7 人。会议的召集、召开和表决程序符合《中 华人民共和国公司法》（以下简称"《公司法》"）等法律法规及规范性文件和《康 希诺生物股份公司章程》（以下简称"《公司章程》"）的规定，合法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一）《关于 2024 年度董事会工作报告的议案》 公司董事会在 2024 年度一直认真履行《公司法》等法律、法规以及《公司章 程》赋予董事会的职责，严格执行股东大会决议，积极推进董事会决议的实施， ...

康希诺生物股份公司董事会 康希诺生物股份公司 2025 年 3 月 25 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等要求，公司董事会就在任独立董事 Yiu Leung Andy CHEUNG （张耀樑）、桂水发、刘建忠的独立性情况进行评估并出具如下专项意见： 经核查独立董事 Yiu Leung Andy CHEUNG（张耀樑）、桂水发、刘建忠的任 职经历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东公司担任任何职务，与公司及其主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立 性的情况，符合《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》中对独立董事独立性的相关要求。 董事会关于独立董事独立性自查情况的专项报告 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-011 康希诺生物股份公司 2024 年度募集资金存放与实际使用情况专项报告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）董事会根据中国证券监督管理委 员会（以下简称"证监会"）《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》及《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》等有关规定，编制了截至 2024 年 12 月 31 日止公开发行 A 股股票 募集资金存放与实际使用情况的专项报告。现将截至 2024 年 12 月 31 日止募集 资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 经中国证监会《关于同意康希诺生物股份公司首次公开发行股票注册的批复》 （证监发行字[2020]1448 号文）核准，公司在上海证券交易所公开发行人民币普 通股（A 股）股票 24,800,000 股，每股发行价格为人民币 209.71 元，股票发行募 集资金总额为人民币 5,200,808 ...

Financial Performance - The company reported a net loss for the period, continuing its trend of not achieving profitability since its listing [3]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2024, representing a 15% increase compared to the previous year [14]. - The company achieved operating revenue of RMB 846,338,072.24 in 2024, a year-on-year increase of 137.01% [25]. - The net loss attributable to shareholders of the listed company was RMB 378,884,001.37, a decrease in loss of 74.45% compared to the previous year [25]. - The total assets at the end of 2024 were RMB 7,958,132,235.38, a decrease of 14.60% year-on-year [25]. - The basic earnings per share for 2024 was -RMB 1.53, compared to -RMB 6.01 in 2023 [24]. - The gross margin for the current fiscal year is reported at 60%, maintaining a stable level compared to last year [22]. - The total net profit from non-recurring items for 2024 was RMB 62,366,451.62, compared to RMB 128,356,172.58 in 2023 [31]. Research and Development - The company continues to focus on research and development of new products and technologies, although specific financial metrics are not provided in the current report [3]. - The R&D department is focusing on the development of a new mRNA vaccine, with an expected completion date for clinical trials in Q3 2024 [17]. - The company has allocated RMB 300 million for research and development in the upcoming year, a 30% increase from the previous budget [20]. - Research and development expenses accounted for 60.35% of operating revenue, a decrease of 124.95 percentage points from the previous year [24]. - The company has established five major technology platforms for vaccine research and development, enhancing its competitive product portfolio [72]. - The company has received 7 new patents during the reporting period, bringing the total number of granted patents to 57 [78]. - The company is focusing on the development of high-quality vaccine products to replace imports in developed markets, with specific products like MCV2 and MCV4 showing promising safety and immunogenicity [165]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2025 [18]. - The company projects a revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies [16]. - The company is advancing its internationalization efforts, targeting Southeast Asia, the Middle East, North Africa, and South America for the commercialization of its quadrivalent meningococcal conjugate vaccine MCV4, which received registration in Indonesia in December 2024 [40]. - The company is exploring new strategies for market expansion and product development to enhance its competitive position in the vaccine industry [138]. - The company is actively expanding its product pipeline with various vaccines in different clinical stages, including those for meningitis and tuberculosis [45]. Corporate Governance - The board of directors confirmed the absence of any profit distribution plan or capital reserve transfer to increase share capital for the reporting period [5]. - The company has not disclosed any special arrangements regarding corporate governance [5]. - The company has established a governance structure that complies with regulatory requirements, ensuring effective operation and accountability [173]. - The company has proposed a profit distribution plan for the year 2023, which is currently under review [175]. - The company has not reported any changes in the governance structure of its red-chip architecture during the reporting period [176]. Risk Factors and Financial Management - The company has identified significant risk factors that may adversely affect its operations, as detailed in the management discussion section [3]. - The company is exposed to financial risks, including currency exchange risks related to overseas operations and potential asset impairment risks [96]. - The company has implemented strict risk control measures for derivative trading, ensuring that the scale and direction of trades match the hedged foreign exchange assets [157]. - The company is committed to improving operational efficiency through resource focus and cost control measures [170]. Product Development and Clinical Trials - The company is conducting Phase I clinical trials for a recombinant shingles vaccine in Canada, utilizing adenovirus vector technology to stimulate both cellular and humoral immunity, with production adhering to international quality standards [39]. - The company has completed Phase I clinical trials for PBPV (pneumococcal vaccine) with positive preliminary results [45]. - The company is advancing multiple vaccine projects, including a recombinant polio vaccine currently in clinical trials in Indonesia [84]. - The company has received acceptance for the drug registration application of PCV13, a 13-valent pneumococcal conjugate vaccine, indicating progress in its R&D pipeline [139]. Sales and Marketing - The company has established partnerships with three major healthcare organizations to enhance distribution channels and improve vaccine accessibility [23]. - The sales revenue from the two meningococcal conjugate vaccines reached approximately 793.79 million RMB, representing a year-on-year growth of 41.31% [35]. - The company is enhancing its corporate governance framework to align with best practices in the industry [181]. - The company is expanding its market presence in Asia, aiming to increase market share by 15% over the next two years [185]. Operational Efficiency - The company has optimized resource allocation, leading to a decrease in management and research expenses, and improved operational efficiency [26]. - The company reported a significant reduction in lease liabilities by 92.76% to ¥12,675,754.57 due to the exclusion of a subsidiary from consolidation [128]. - The company is committed to advancing the commercialization of existing products while maintaining significant investment in R&D for future pipeline products [93]. - The company has seen a trend of decreasing procurement amounts from the top five suppliers since 2023, indicating a diversification in supplier relationships [119]. Shareholder Engagement - The company held its first extraordinary shareholders' meeting of 2024 on February 21, where the third board of directors and the third supervisory board were elected [180]. - The company has proposed to revise its shareholder dividend return plan for the next three years (2023-2025) [1]. - The company has not reported any dissenting votes on the proposals presented at the shareholders' meeting, indicating strong shareholder support [175].

康希诺:2024年报净利润-3.79亿 同比增长74.44% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -1.5300 | -6.0100 | 74.54 | -3.6800 | | 每股净资产（元） | 0 | 21.32 | -100 | 27.27 | | 每股公积金(元) | 26.58 | 26.57 | 0.04 | 26.7 | | 每股未分配利润(元) | -7.83 | -6.30 | -24.29 | -0.31 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.46 | 3.57 | 136.97 | 10.35 | | 净利润(亿元) | -3.79 | -14.83 | 74.44 | -9.09 | | 净资产收益率(%) | -7.44 | -24.67 | 69.84 | -12.36 | 数据四舍五入，查看更多财务数据>> | 持有数量(万股) 名称 ...